Stefan Knackmuss has more than 20 years of biotech experience spanning from research, early and late-stage preclinical development. He has a background in Biochemistry and Molecular Biology and received his PhD from the University of Heidelberg, Germany at the Institute of Molecular Genetics. After a postdoctoral year Stefan joined Affimed, a clinical stage and publicly listed company with a focus on bispecific antibodies harnessing the innate and adaptive immune system for treatment of various cancers. As a Head of Preclinical Development, he was instrumental in advancing multiple bispecific antibodies to IND-filing.